7.3 Upper Tract Urothelial Carcinoma (UTUC)

7.3 Upper Tract Urothelial Carcinoma (UTUC)

Upper tract urothelial carcinomas (UTUC) arise from the urothelial lining of the pyelocaliceal cavities and ureter. Although sharing histopathological characteristics with bladder cancer, UTUC exhibits distinct epidemiological, biological, anatomical, and genetic features. Because the smooth muscle wall of the renal pelvis and ureter is exceedingly thin compared to the robust detrusor muscle of the urinary bladder, more than 60% of UTUC patients present with muscle-invasive or locally advanced disease at initial diagnosis, compared to only 15% to 25% of patients with bladder urothelial tumors.

---

1. Epidemiology & Etiological Risk Factors

UTUC is relatively rare, accounting for 5% to 10% of all urothelial cancers, with an estimated annual incidence of 1 to 2 cases per 100,000 person-years. Pyelocaliceal tumors are approximately twice as common as ureteral tumors. There is a strong male predilection (male-to-female ratio ~2:1 to 3:1), with peak clinical incidence occurring in the seventh and eighth decades of life.

Field Cancerization & Recurrence Dynamics

• Synchronous or Metachronous Upper Tract Tumors: Bilateral synchronous UTUC occurs in 1% to 5% of patients, whereas metachronous contralateral recurrence occurs in 2% to 6%.
• Subsequent Bladder Recurrence: Following primary surgical treatment of UTUC, intravesical bladder recurrence develops in 22% to 47% of patients. Postulated mechanisms include downstream intraluminal tumor seeding (exfoliation of viable cancer cells that implant onto traumatized urothelial mucosa) and pan-urothelial field cancerization.

Specific Environmental & Chemical Exposures

• Tobacco Smoking: The principal avoidable risk factor, increasing the relative risk of UTUC 2.5- to 7-fold in a dose- and duration-dependent manner.
• Aristolochic Acid Nephropathy (AAN): Occurs following exposure to aristolochic acid, a nephrotoxic and carcinogenic alkaloid found in Aristolochia plants:
  • Balkan Endemic Nephropathy (BEN): Historically endemic to farming villages along the Danube river basin where Aristolochia clematitis contaminated wheat flour harvests.
  • Chinese Herbal Nephropathy: Linked to slimming regimens and traditional remedies containing Aristolochia fangchi.
  • Molecular Signature: Aristolochic acid reacts with DNA to form covalent 7-(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) adducts, producing a distinctive and virtually unique $A:T \rightarrow T:A$ transversion mutation in the TP53 tumor suppressor gene. AA exposure markedly increases UTUC risk and can cause extensive tubulointerstitial fibrosis; bilateral or multifocal tumours may occur.
• Phenacetin Abuse: Excessive historical consumption of phenacetin-containing analgesics promotes severe renal papillary necrosis and carries a high risk of renal pelvic and ureteral urothelial malignancies.

Hereditary Syndromes: Lynch Syndrome (HNPCC)

• Genetic Basis: Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by germline mutations in DNA mismatch repair (MMR) genes: MSH2, MLH1, MSH6 and PMS2; EPCAM deletions can silence MSH2. UTUC is particularly associated with MSH2 carriers.
• Risk Profile: UTUC represents the third most frequent malignancy in Lynch syndrome families (behind colorectal adenocarcinoma and endometrial cancer), with risk varying substantially by the affected gene and age.
• EAU Screening Recommendations: Assess personal and family history in every patient. Suspicion is raised by age <60, a personal Lynch-spectrum cancer, one first-degree relative diagnosed with a Lynch-related cancer before 50, or two first-degree relatives at any age. Refer suspected hereditary UTUC for germline sequencing and counselling. EAU also weakly recommends offering tumour MMR-IHC or MSI testing when clinical suspicion is absent; abnormal tumour testing prompts germline evaluation.

---

2. Diagnostic Pathways & Imaging Modalities

Haematuria / flank pain / suspicious upper-tract imaging
                 │
                 ▼
Cystoscopy + urine cytology + CT urography
(MR urography if CT/iodinated contrast is unsuitable)
                 │
                 ▼
URS ± targeted biopsy / selective cytology when needed
for diagnosis, mapping or risk stratification
                 │
                 ▼
Grade + imaging invasion + other EAU risk factors
         ┌───────┴─────────────────┐
         ▼                         ▼
Low-risk disease          Strong high-risk features
Kidney-sparing            Usually RNU + bladder cuff
management                + site-specific regional LND
         └──── Weak high-risk features alone ────┘
          Individual KSS/RNU discussion if low grade

Clinical Presentation

• Microscopic or Macroscopic Hematuria: Present in 70% to 80% of patients.
• Flank Pain: Occurs in 20% to 40% of cases, typically secondary to ureteral luminal obstruction by tumor bulk, blood clots, or accompanying hydronephrosis.
• Constitutional Symptoms: Weight loss, anorexia, fever, night sweats, or a palpable flank mass indicate locally advanced or metastatic disease.

Contrast-Enhanced Computed Tomography Urography (CTU)

• Diagnostic Gold Standard: EAU cites pooled CTU sensitivity of 92% and specificity of 95%. Flat CIS without a mass or wall thickening may be invisible; cystoscopy is also required to assess concomitant bladder cancer.
• Typical CTU Phases (protocols may combine phases to limit radiation):
  1. Unenhanced Phase: Identifies radio-opaque calculi that could mimic or obscure soft-tissue urothelial filling defects.
  2. Nephrographic Phase (90–100 seconds): Evaluates renal parenchymal invasion, cortical distortion, and regional retroperitoneal lymphadenopathy.
  3. Excretory Phase (delayed 10–15 minutes): Visualizes contrast filling of the calyces, renal pelvis, and entire ureteral lumina, revealing intraluminal soft-tissue filling defects, concentric ureteral wall thickening, mucosal irregularity, or caliceal amputation.

Magnetic Resonance Urography (MRU) & Retrograde Pyelography

• MR Urography: Used when CTU, radiation or iodinated contrast is unsuitable. Renal impairment requires an individual contrast-risk assessment; eGFR <30 is not an automatic prohibition of every contrast study, and MR contrast suitability must also be assessed.
• Retrograde Pyelography: Indicated when CTU is inconclusive, when contrast cannot be given, or as an adjunct during ureterorenoscopy to define collecting system anatomy.

Diagnostic Flexible Ureterorenoscopy (URS) & Cytology

• Role of URS: Use when imaging and voided cytology do not sufficiently establish diagnosis or risk. It maps size, focality and architecture and allows targeted sampling, especially before KSS. Routine biopsy is not mandatory when adequate imaging/cytology already determines management.
• Selective Cytology: Barbotage cytology obtained directly from the renal pelvis or ureter via a ureteral catheter prior to contrast injection has higher diagnostic sensitivity (>80% for high-grade tumors) than voided urine cytology.
• Endoscopic Biopsy: Acquired using nitinol stone baskets or dedicated flexible biopsy forceps (e.g., BIGopsy). Biopsy can determine grade in over 90% of cases, but undergrading and understaging occur compared with RNU specimens. Small samples often lack adequate lamina propria; combine biopsy with imaging and cytology rather than treating a low-grade sample as proof against invasion.

---

3. EAU Risk Stratification: Low-Risk vs High-Risk UTUC

The EAU Guidelines classify UTUC into Low-Risk and High-Risk categories to guide the critical therapeutic decision between kidney-sparing surgery and radical nephroureterectomy:

Low-Risk UTUC Criteria

A tumor is classified as Low-Risk ONLY IF ALL of the following criteria are met:

1. Unifocal disease (single lesion).
2. Tumor size < 2 cm (< 20 mm).
3. Cytology negative for high-grade carcinoma.
4. Low-grade biopsy histopathology.
5. Non-invasive on CTU (absence of parenchymal infiltration or peripelvic/periureteral fat infiltration).

High-Risk UTUC Criteria

Strong criteria are high-grade cytology, high-grade URS biopsy, local invasion on CT, or an adverse histological subtype (e.g., micropapillary, sarcomatoid or neuroendocrine differentiation).

Weak criteria are multifocality, tumour size $\ge$ 2 cm and hydronephrosis. They add concern, but individually are not strong predictors of invasion when disease is low grade. Do not automatically mandate RNU for an otherwise non-infiltrative low-grade tumour on the basis of one weak feature. A prior high-grade bladder cancer/cystectomy affects recurrence risk and follow-up but is not a standalone criterion in the current EAU progression-risk figure.

---

4. Surgical Decision-Making & Operative Principles

Kidney-Sparing Surgery (KSS) for Low-Risk UTUC

Kidney-sparing surgery aims to preserve renal function, avoid the cardiovascular morbidity associated with end-stage renal disease, and eliminate the need for hemodialysis without compromising oncological control in carefully selected low-risk patients:

• Endoscopic Laser Ablation:
  • Retrograde Flexible URS: Ho:YAG or thulium lasers ablate accessible low-grade papillary lesions. Low-power Ho:YAG settings such as 0.6–1.0 J at about 8–10 Hz are examples, not a universal prescription; ensure complete ablation while limiting thermal injury to the thin wall.
  • Percutaneous Antegrade Approach: Consider for low-risk renal pelvic/calyceal lesions that are inaccessible or difficult to treat retrogradely; size alone does not establish a fixed >1.5 cm indication. Discuss the uncommon risk of tract seeding.
• Segmental Ureteric Resection (Distal Ureterectomy):
  • Indicated for unifocal low-risk tumors confined to the distal ureter.
  • Involves wide local excision of the distal ureter, ipsilateral bladder cuff, and ureteroneocystostomy with a psoas hitch or Boari flap to ensure a tension-free anastomosis.
• Surveillance Protocol After KSS: Perform second-look URS within eight weeks after endoscopic treatment. For low-risk disease after a negative second look, EAU suggests cystoscopy and CTU at three and six months, then yearly for five years, with or without additional URS. High-risk KSS needs more intensive urographic/URS follow-up; the optimal role of repeated URS is uncertain. All schedules depend on risk and treatment.

Radical Nephroureterectomy (RNU) for High-Risk UTUC

RNU with a formal bladder cuff is standard for high-risk non-metastatic UTUC. Selected distal high-risk tumours may undergo distal ureterectomy; imperative renal-preservation indications or predominantly weak high-risk features may justify individualized KSS after discussion of progression risk.

• Surgical Boundaries: En-bloc excision of the kidney, surrounding perinephric and Gerota's fat, the entire length of the ipsilateral ureter down to the ureterovesical junction, and a contiguous bladder cuff.
• The Bladder Cuff Mandate:
  • Remove the entire distal/intramural ureter and ureteric orifice with a bladder cuff; a retained stump carries substantial recurrence risk.
  • Open transvesical or extravesical dissection must achieve complete cuff excision and a watertight bladder closure. Avoid urinary/tumour spillage, with early ureteric clipping and bladder drainage before opening the urinary tract.
  • Simplified endoscopic “pluck”, stripping or similar techniques have not convincingly demonstrated equivalence to complete cuff excision. The oncological endpoint is complete removal, not simply detaching or stapling across the ureteric orifice.

Regional Template Lymphadenectomy

Template-based LND improves staging; observational data suggest better regional control and possibly cancer-specific survival, but high-level evidence of a survival benefit is lacking. EAU gives a weak recommendation for template LND in high-risk non-metastatic disease. Templates depend on site and laterality:

• Right Renal Pelvis / Proximal Ureter: Renal hilar, paracaval and retrocaval nodes, with interaortocaval extension according to the selected template.
• Left Renal Pelvis / Proximal Ureter: Renal hilar and para-aortic/preaortic nodes, with extension as appropriate.
• Mid-Ureteral Tumours: Adapt the retroperitoneal/pelvic field to level and laterality; do not apply one renal-pelvis-to-IMA boundary to every upper two-thirds ureteral tumour.
• Distal Ureter: Ipsilateral pelvic basins, including iliac and obturator nodes. This is not bilateral bladder-cancer PLND for every UTUC site.

---

5. Perioperative Systemic & Intravesical Chemotherapy

Prevention of Bladder Recurrence: Single Post-Operative Intravesical Instillation

• The ODMIT-C Trial (Level 1 Evidence):
  • A prospective, multicenter randomized controlled trial evaluated a single post-operative intravesical instillation of mitomycin C (40 mg in 40 mL saline) administered at urinary catheter removal after RNU in patients without previous or concurrent bladder cancer.
  • Results: At one year, modified intention-to-treat recurrence was 17% versus 27% (p=0.055); per-protocol recurrence was 16% versus 27% (p=0.03). The authors reported about 11 percentage points absolute reduction, 40% relative reduction and NNT 9. Do not mix the two analyses.
  • EAU Recommendation: Offer one postoperative intravesical chemotherapy dose to eligible patients without a history of bladder cancer. Trials used MMC or pirarubicin two to ten days after surgery; ODMIT-C instilled MMC at catheter removal, not after loss of catheter access. Consider cystography if extravasation is a concern and withhold drug if leakage is suspected.

Adjuvant Systemic Chemotherapy: The POUT Trial

• Trial Architecture & Patient Population:
  • The POUT trial was a phase III randomized controlled trial comparing surveillance versus adjuvant platinum-based systemic chemotherapy in patients with locally advanced, muscle-invasive (pT2–pT4 and/or node-positive, M0; trial-era nodal categories included N1–3) UTUC following radical nephroureterectomy.
  • Chemotherapy regimen consisted of 4 cycles of gemcitabine plus cisplatin (or gemcitabine plus carboplatin if GFR was 30–49 mL/min) initiated within 90 days of surgery.
• Outcomes & Survival Impact:
  • Adjuvant chemotherapy produced a dramatic, statistically significant 55% reduction in the relative risk of disease recurrence or death (disease-free survival hazard ratio 0.45, 95% CI 0.30–0.68, p = 0.0001).
  • Three-year disease-free survival was 71% in the chemotherapy arm versus 46% in the surveillance arm.
  • The 2024 final analysis found five-year DFS 62% versus 45% (HR 0.55), with treatment effects consistent across planned cisplatin/carboplatin regimens. Platinum type was selected by renal function, not randomized; POUT does not establish a direct cisplatin-versus-carboplatin superiority comparison.
• Clinical Practice Standard: Offer adjuvant platinum combination chemotherapy after RNU to eligible pT2–T4 and/or pN+ patients. Eligibility includes performance status, hearing, neuropathy and cardiac reserve as well as renal function. Carboplatin in this adjuvant UTUC setting is supported by POUT; it must not be confused with unsupported carboplatin NAC substitution in MIBC.

---

6. UTUC Decision Matrix & Landmark Trials Table

EAU UTUC Risk Stratification and Management Table

Landmark Clinical Trials in UTUC Multimodal Management